Focused On-demand Library for Succinate dehydrogenase assembly factor 1, mitochondrial

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

A6NFY7

UPID:

SDHF1_HUMAN

Alternative names:

LYR motif-containing protein 8

Alternative UPACC:

A6NFY7; B2RPM7

Background:

Succinate dehydrogenase assembly factor 1, mitochondrial, also known as LYR motif-containing protein 8, is pivotal in the assembly of succinate dehydrogenase (SDH). This enzyme complex is integral to both the tricarboxylic acid (TCA) cycle and the mitochondrial electron transport chain, facilitating the oxidation of succinate to fumarate and the reduction of ubiquinone to ubiquinol. It ensures the maturation of the SDHB subunit, safeguarding it against oxidative damage, and aids in iron-sulfur cluster incorporation into SDHB.

Therapeutic significance:

Mitochondrial complex II deficiency, nuclear type 2, linked to this protein, manifests in diverse clinical symptoms, from severe multisystem involvement to isolated cardiac or muscle issues. Understanding the role of Succinate dehydrogenase assembly factor 1 could open doors to potential therapeutic strategies, offering hope for targeted treatments for this and related mitochondrial disorders.